RecruitingPhase 1NCT05886049
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
Studying Acute myeloid leukemia with 11q23 abnormalities
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Alice S MimsOhio State University Comprehensive Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 28 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2027
Study locations (22)
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Kansas Clinical Research Center, Fairway, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05886049 on ClinicalTrials.govOther trials for Acute myeloid leukemia with 11q23 abnormalities
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06710418Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/LeukemiaUniversity of Washington
- RECRUITINGPHASE3NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLKura Oncology, Inc.
- RECRUITINGPHASE1, PHASE2NCT06928662Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07106749CD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT06448013A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06245746UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06452732Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLPeking University People's Hospital
- RECRUITINGNCT06458257The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid LeukemiaRuijin Hospital
See all trials for Acute myeloid leukemia with 11q23 abnormalities →